PVLA
$120.80
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Intraday
Recent News
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple
Palvella Therapeutics stock reacts to recent performance metrics Palvella Therapeutics (PVLA) has drawn fresh attention after recent performance metrics showed a 1-day return of an 8.98% decline, alongside strong gains over the past week, month, and past 3 months. See our latest analysis for Palvella Therapeutics. Despite the latest 1 day share price return showing an 8.98% decline to US$135.02, the stock still has strong recent momentum, with a 30 day share price return of 76.06% and a year...
Top Midday Gainers
Enerflex (EFXT) said late on Wednesday its preliminary 2026 outlook "reflects steady demand across i
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstrating a statistically significant 2.13-point mean change, is “a clear and decisive win,” says the analyst, who believes that the efficacy demonstrated in the SELVA trial will likely result in strong and continued uptake among patients if approved.Claim 50% Off TipRanks PremiumUnlock hedge fund-level da
Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin
Palvella Therapeutics (NASDAQ:PVLA) said it reported positive top-line results from its phase III SELVA study evaluating QTORIN 3.9% rapamycin in hydrogel as a once-daily topical treatment for microcystic lymphatic malformations (mLM), a rare, serious, and chronically debilitating genetic disease wi
Why Top 2% Palvella Therapeutics, Up 33%, Just Blew Past Its 50-Day Line
Biotech stock Palvella Therapeutics surged Tuesday on positive test results for its experimental skin disease treatment.